Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

Influence of related genetic polymorphisms to pharmacokinetics and pharmacodynamics of Fluvastatin

The Influence of Genetic Polymorphisms in Drug Metabolism Enzymes and Transporters on the Pharmacokinetics of Different Fluvastatin Formulations

The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis.

CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T Are Determinants of Inter-Subject Variability in Fluvastatin Pharmacokinetics in Healthy Chinese Volunteers.

Associations between SLCO1B1, APOE and CYP2C9 and lipid-lowering efficacy and pharmacokinetics of fluvastatin: a meta-analysis

Relationship between the polymorphisms in the cholesterol ester transfer protein gene and the effect of fluvastatin

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

Progress in research of cytochrome P450 3A4 gene polymorphism

Simvastatin Pharmacokinetics in Healthy Chinese Subjects and Its Relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 Polymorphisms.

Modeled Hepatic/Plasma Exposures of Fluvastatin Prescribed Alone in Subjects with Impaired Cytochrome P450 2C9*3 as One of Possible Determinant Factors Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database

Study on pharmacokinetics of fluvastatin in healthy subjects after single and multiple doses of porolonged-extended release fluvastatin and immediate-release fluvastatin

CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 Genetic Polymorphisms and Gender Are Determinants of Inter-Subject Variability in Pitavastatin Pharmacokinetics.

ABCB1 Gene Polymorphisms, ABCB1 Haplotypes and ABCG2 C.421c > A Are Determinants of Inter-Subject Variability in Rosuvastatin Pharmacokinetics.

Associations of Two Common Polymorphisms in MTHFR Gene with Blood Lipids and Therapeutic Efficacy of Simvastatin.

Research progress of voriconazole pharmacokinetics based on gene polymorphisms

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

Systematic Review of Influence on Pharmacokinetics of Voriconazole on CYP2C19 Genetic Polymorphisms

Association Between SLCO1B1 T521C Polymorphism and Risk of Statin-Induced Myopathy: a Meta-Analysis

Effect of CYP2C19 Genetic Polymorphism on Lansoprazole Pharmacokinetics:A Systematic Review

Impact of CYP2C19, CYP2C9, CYP3A4, and FMO3 Genetic Polymorphisms and Sex on the Pharmacokinetics of Voriconazole after Single and Multiple Doses in Healthy Chinese Subjects

Systematic Review of Influence of CYP2C19 Genetic Polymorphism on Pharmacokinetics of Omeprazole